<DOC>
	<DOC>NCT02992678</DOC>
	<brief_summary>Between December 2016 and June 2017, 110 consecutive patients older than 18 years who are scheduled to undergo diagnostic or therapeutic ERCP at the Anhui Provincial Hospital will be recruited for the study. Patients were randomized using opaque, sealed envelopes containing random numbers assigning them to treat with pentoxifylline (pentoxifylline group) or Placebo (placebo group) for preventing ERCP pancreatitis.</brief_summary>
	<brief_title>Pentoxifylline for the Prevention of PEP</brief_title>
	<detailed_description />
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>1. Males and females, age &gt; 18 years. 2. Normal amylase level before undergoing ERCP. 3. Signed inform consent form and agreed to followup on time. 1. Medical or psychological condition that would not permit the patient to complete the study or sign the informed consent. 2. Patients involved in other study within 60 days. 3. Billroth II or RouxenY anatomy 4. Acute pancreatitis. 5. a history of previous ERCP 6. Pregnancy or history of allergy to pentoxifylline 7. Patient treated for arterial hypertension 8. Patient with severe coagulopathy 9. Patient with hyper sensibility of pentoxifylline 10. Nursing mothers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>